Development And Evaluation Of Immediate Release Granules For Management Of Hypertension

Abstract

The objective of this work was to formulate and evaluate immediate release granules of Hydrochlorothiazide with Preformulation study for the management of hypertension. A diuretic drug called hydrochlorothiazide is used to alleviate swelling brought on by fluid accumulation and hypertension. Additional applications include the management of renal tubular acidosis and diabetic insipidus, as well as the reduction of kidney stone risk in individuals with elevated urine calcium levels. A thiazide drug called hydrochlorothiazide causes a natriuresis by preventing sodium and chloride ions from being reabsorbed from the kidneys' distal convoluted tubules. Hydrochlorothiazide's weak solubility and wettability contribute to its poor dissolution. Using the solid dispersion approach, the physicochemical properties of hydrochlorothiazide were improved in this study. PEG 6000 polymer was used to formulate a solid hydrochlorothiazide dispersion at three different drug: polymer ratios: 1:1, 1:2, and 1:3. The Hydrochlorothiazide Preformulation Study comprised a study of the drug's polymer interactions, standard calibration curves, melting point, and FTIR analysis. Wet granulation was used to make the hydrochlorothiazide quick release granules using varying amounts of croscarmellose sodium, a superdisintegrant. The highest solubility was observed in the solid dispersion (1:3). Formulation A4 for instant release granules displayed a maximum of 96. In 30 minutes, release. Thus, it was decided that SD3 and A4 were the optimum formulation.